FR2621487B1 - Virus avipox recombinant - Google Patents

Virus avipox recombinant

Info

Publication number
FR2621487B1
FR2621487B1 FR888811334A FR8811334A FR2621487B1 FR 2621487 B1 FR2621487 B1 FR 2621487B1 FR 888811334 A FR888811334 A FR 888811334A FR 8811334 A FR8811334 A FR 8811334A FR 2621487 B1 FR2621487 B1 FR 2621487B1
Authority
FR
France
Prior art keywords
avipox virus
recombinant avipox
recombinant
virus
avipox
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR888811334A
Other languages
English (en)
French (fr)
Other versions
FR2621487A1 (fr
Inventor
Enzo Paoletti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Health Research Inc
Original Assignee
Health Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27492413&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2621487(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Health Research Inc filed Critical Health Research Inc
Publication of FR2621487A1 publication Critical patent/FR2621487A1/fr
Application granted granted Critical
Publication of FR2621487B1 publication Critical patent/FR2621487B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FR888811334A 1987-08-28 1988-08-29 Virus avipox recombinant Expired - Lifetime FR2621487B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9071187A 1987-08-28 1987-08-28
US11033587A 1987-10-20 1987-10-20
US18605488A 1988-04-25 1988-04-25
US23439088A 1988-08-23 1988-08-23

Publications (2)

Publication Number Publication Date
FR2621487A1 FR2621487A1 (fr) 1989-04-14
FR2621487B1 true FR2621487B1 (fr) 1991-10-18

Family

ID=27492413

Family Applications (1)

Application Number Title Priority Date Filing Date
FR888811334A Expired - Lifetime FR2621487B1 (fr) 1987-08-28 1988-08-29 Virus avipox recombinant

Country Status (17)

Country Link
JP (3) JP3348156B2 (https=)
KR (1) KR970011149B1 (https=)
AR (1) AR241939A1 (https=)
AT (1) AT408549B (https=)
AU (2) AU2427588A (https=)
BE (1) BE1002134A5 (https=)
CH (2) CH679934A5 (https=)
DE (4) DE10399032I1 (https=)
DK (1) DK175904B1 (https=)
FR (1) FR2621487B1 (https=)
GB (1) GB2217718B (https=)
IL (1) IL87581A0 (https=)
IT (1) IT1229484B (https=)
LU (2) LU90951I2 (https=)
NL (4) NL195051C (https=)
NZ (1) NZ225970A (https=)
WO (1) WO1989003429A1 (https=)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5505941A (en) * 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US5338683A (en) * 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
DE10399032I1 (de) * 1987-08-28 2004-01-29 Health Research Inc Rekombinante Viren.
US5286639A (en) * 1987-09-16 1994-02-15 Nippon Zeon Co., Ltd. Recombinant avipoxvirus
DE3813093A1 (de) * 1988-04-19 1989-11-09 Immuno Ag Rekombinantes plasmid, verfahren zum herstellen eines rekombinanten avipoxvirus, rekombinantes avipoxvirus und dessen verwendung
US5631154A (en) * 1988-06-10 1997-05-20 Therion Biologics, Incorporated Self assembled, defective, non-self-propagating lentivirus particles
JP2538367B2 (ja) * 1988-06-24 1996-09-25 ブリティッシュ・テクノロジー・グループ・リミテッド Ｆｏｗｌｐｏｘウィルスの非必須領域
US5093258A (en) * 1988-08-26 1992-03-03 Therion Biologics Corporation Recombinant fowlpox virus and recombination vector
CA2001001A1 (en) * 1988-10-21 1990-04-21 Matthew M. Binns Fowlpox virus promoter
US6248333B1 (en) 1990-04-04 2001-06-19 Health Research Inc. Isolated nucleic acid sequence of equine herpesvirus type 1 glycoprotein D (EHV-1 gD)
US5204243A (en) * 1990-02-14 1993-04-20 Health Research Incorporated Recombinant poxvirus internal cores
MY109299A (en) * 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5514375A (en) * 1990-08-15 1996-05-07 Virogenetics Corporation Flavivirus recombinant poxvirus vaccine
FR2668064B1 (fr) * 1990-10-23 1994-12-16 Transgene Sa Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.
IE68404B1 (en) * 1990-11-20 1996-06-12 Virogenetics Corp Measles virus recombinant poxvirus vaccine
US6309647B1 (en) 1999-07-15 2001-10-30 Aventis Pasteur Poxvirus—canine dispemper virus (CDV) or measles virus recombinants and compositions and methods employing the recombinants
US5503834A (en) * 1990-11-20 1996-04-02 Virogenetics Corporation Measles virus recombinant poxvirus vaccine
US5759841A (en) * 1990-11-20 1998-06-02 Virogenetics Corporation Immunological composition of measles virus utilizing recombinant poxvirus
US5756102A (en) * 1990-11-20 1998-05-26 Virogenetics Corporation Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants
US5338679A (en) * 1991-01-08 1994-08-16 Her Majesty The Queen In Right Of Canada, As Represented By National Research Council Canada And Forestry Canada Vertebrate poxvoris expression vector under the control of entomopoxvirus spheroidin gene promoter
US5766598A (en) * 1991-03-07 1998-06-16 Virogenetics Corporation Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products
US5766597A (en) * 1991-03-07 1998-06-16 Virogenetics Corporation Malaria recombinant poxviruses
AU672581B2 (en) * 1991-03-07 1996-10-10 Virogenetics Corporation Immunodeficiency virus recombinant poxvirus vaccine
DE69233158T2 (de) * 1991-03-07 2004-05-13 Connaught Technology Corp., Greenville Gentechnologisch hergestellter stamm für impfstoffe
US5863542A (en) * 1991-03-07 1999-01-26 Virogenetics Corporation Recombinant attenuated ALVAC canaryopox virus containing heterologous HIV or SIV inserts
US5756101A (en) * 1991-07-01 1998-05-26 Pasteur Merieux Serums Et Vaccins Malaria recombinant poxvirus
AU674491B2 (en) * 1991-03-20 1997-01-02 Virogenetics Corporation Recombinant poxvirus malaria vaccine
WO1993003145A1 (en) * 1991-07-26 1993-02-18 Virogenetics Corporation Infectious bursal disease virus recombinant poxvirus vaccine
DK0538496T3 (da) * 1991-08-26 2004-02-23 Baxter Healthcare Sa Rekombinant fjerkrækoppevirus med intakt FPV tk-gen
US5443831A (en) * 1991-10-29 1995-08-22 University Of Delaware Gene encoding glycoprotein B of Infectious Laryngotracheitis Virus
CA2127700C (en) * 1992-01-13 2006-06-20 Enzo Paoletti Marek's disease virus recombinant poxvirus vaccine
US6033904A (en) * 1992-01-13 2000-03-07 Syntro Corporation Recombinant swinepox virus
US6251403B1 (en) 1992-01-13 2001-06-26 Syntro Corporation Recombinant swinepox virus
US6497882B1 (en) 1992-01-13 2002-12-24 Syntro Corporation Recombinant swinepox virus
US5869312A (en) * 1992-01-13 1999-02-09 Syntro Corporation Recombinant swinepox virus
US6127163A (en) * 1992-01-13 2000-10-03 Syntro Corporation Recombinant swinepox virus
US6328975B1 (en) 1992-01-13 2001-12-11 Syntro Corporation Recombinant swinepox virus
CA2142325A1 (en) * 1992-09-21 1994-03-31 William T. L. Lee Recombinant retroviral vector against felv and/or fiv
AU727278B2 (en) * 1993-02-26 2000-12-07 Syntro Corporation Recombinant fowlpox viruses and uses thereof II
US5925358A (en) * 1993-02-26 1999-07-20 Syntro Corporation Recombinant fowlpox viruses and uses thereof
US6136318A (en) * 1993-02-26 2000-10-24 Cochran; Mark D. Recombinant fowlpox viruses and uses thereof
AU6299594A (en) * 1993-02-26 1994-09-14 Nippon Zeon Co., Ltd. Recombinant fowlpox virus s-fpv-043 and uses thereof
US5496731A (en) * 1993-03-25 1996-03-05 Xu; Hong-Ji Broad-spectrum tumor suppressor genes, gene products and methods for tumor suppressor gene therapy
US5843742A (en) * 1994-12-16 1998-12-01 Avigen Incorporated Adeno-associated derived vector systems for gene delivery and integration into target cells
EP0753581A1 (en) 1995-07-10 1997-01-15 Immuno Ag Improved recombinant eukaryotic cytoplasmic viruses, method for their production and their use as vaccines
US5858373A (en) * 1995-12-01 1999-01-12 Virogenetics Corporation Recombinant poxvirus-feline infectious peritionitis virus, compositions thereof and methods for making and using them
AU731860B2 (en) 1996-07-25 2001-04-05 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Recombinant pox virus for immunization against tumor-associated antigens
US6106825A (en) * 1997-05-07 2000-08-22 University Of Florida Entomopoxvirus-vertebrate gene delivery vector and method
WO1999007869A1 (en) * 1997-08-05 1999-02-18 University Of Florida Live recombinant vaccine comprising inefficiently or non-replicating virus
US6248582B1 (en) * 1997-10-08 2001-06-19 Imran Khan Gene deleted recombinant FeLV proviral DNA for production of vaccines against FeLV
JPH11165762A (ja) 1997-12-01 1999-06-22 Lintec Corp チップ体搬送用カバーテープおよび封止構造体
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US6221349B1 (en) 1998-10-20 2001-04-24 Avigen, Inc. Adeno-associated vectors for expression of factor VIII by target cells
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
AU2221600A (en) 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
CA2374610A1 (en) 1999-06-28 2001-01-04 Jordan J. N. Tang Catalytically active recombinant memapsin and methods of use thereof
IL151097A0 (en) 2000-02-23 2003-04-10 Smithkline Beecham Biolog Tumour-specific animal proteins
AR029540A1 (es) 2000-06-28 2003-07-02 Corixa Corp COMPOSICIONES Y METODOS PARA EL DIAGNoSTICO Y LA TERAPIA DE CA NCER DE PULMoN
CA2434546C (en) 2001-01-12 2012-09-11 Chiron Corporation Induction of immune response by a replication-defective venezuelan equine encephalitis-sindbis chimeric virus replicon particle encoding an antigen
BR0207761A (pt) * 2001-03-08 2006-01-31 Akzo Nobel Nv Uso de um vìrus leporipox recombinante vivo, vacina, e, vìrus leporipox recombinante vivo
JP4499311B2 (ja) * 2001-04-27 2010-07-07 シャープ株式会社 放送受信端末
JP2005504513A (ja) 2001-05-09 2005-02-17 コリクサ コーポレイション 前立腺癌の治療及び診断のための組成物及び方法
EP1411770A4 (en) 2001-07-05 2006-05-10 Chiron Corp POLYNUCLEOTIDES CODING FOR ANTIGENIC C-TYPE HIV POLYPEPTIDES, POLYPEPTIDES AND THEIR USE
EP2280074A3 (en) 2001-07-05 2011-06-22 Novartis Vaccines and Diagnostics, Inc. Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof
DK2224012T3 (da) 2001-12-17 2013-05-13 Corixa Corp Sammensætninger og fremgangsmåder til terapi og diagnose af inflammatoriske tarmsygdomme
CN101863930A (zh) 2003-01-06 2010-10-20 科里克萨有限公司 一些氨烷基氨基葡糖苷磷酸酯化合物和它们的用途
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
US20070073048A1 (en) 2003-05-15 2007-03-29 Ying Lian Hiv polynucleotides and polypeptides derived from botswana mj4
US7261882B2 (en) 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
NZ553776A (en) 2004-09-22 2010-05-28 Glaxosmithkline Biolog Sa Immunogenic composition comprising staphylococcal PNAG and Type 5 and/or 8 Capsular polysaccharide or oligosaccharide.
ES2514316T3 (es) 2005-11-22 2014-10-28 Novartis Vaccines And Diagnostics, Inc. Partículas similares a virus (VLPs) de Norovirus y Sapovirus
EP2441846A3 (en) 2006-01-09 2012-07-25 The Regents Of the University of California Immunostimulatory combinations of TNFRSF, TLR, NLR, RHR, purinergic receptor, and cytokine receptor agoinsts for vaccines and tumor immunotherapy
EP2441469A1 (en) 2006-03-14 2012-04-18 Oregon Health and Science University Methods for producing an immune response to tuberculosis
WO2008106551A2 (en) 2007-02-28 2008-09-04 The Govt. Of The U.S.A. As Represented By The Secretary Of The Dept. Of Health & Human Serv. Brachyury polypeptides and methods for use
JP2011500036A (ja) 2007-10-15 2011-01-06 ザ ユニバーシティー オブ クイーンズランド 構築物系およびその使用
US8691502B2 (en) 2008-10-31 2014-04-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
US8425922B2 (en) 2009-01-05 2013-04-23 EpitoGenesis, Inc. Adjuvant compositions and methods of use
WO2010099472A2 (en) 2009-02-27 2010-09-02 The U.S.A. Of America, As Represented By The Secretary, Department Of Health And Human Services Spanx-b polypeptides and their use
CN102713629B (zh) 2009-11-20 2016-02-24 俄勒冈健康科学大学 用于检测结核分枝杆菌感染的方法
US20130052221A1 (en) 2010-02-26 2013-02-28 The Govt. of the U.S, as represented by The Sec. of The Dept. of Health and Human Services Dna-protein vaccination protocols
US9795658B2 (en) 2010-04-20 2017-10-24 Admedus Vaccines Pty Ltd Expression system for modulating an immune response
US9428565B2 (en) 2011-01-31 2016-08-30 The General Hospital Corporation Treatment and bioluminescent visualization using multimodal TRAIL molecules
WO2012151272A2 (en) 2011-05-02 2012-11-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
CA2837651A1 (en) 2011-06-21 2012-12-27 Oncofactor Corporation Compositions and methods for the therapy and diagnosis of cancer
US10561720B2 (en) 2011-06-24 2020-02-18 EpitoGenesis, Inc. Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators
US20150004144A1 (en) 2011-12-02 2015-01-01 The General Hospital Corporation Differentiation into brown adipocytes
WO2014035474A1 (en) 2012-08-30 2014-03-06 The General Hospital Corporation Compositions and methods for treating cancer
WO2014043535A1 (en) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions for the treatment of cancer
WO2014043518A1 (en) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
CA2909706C (en) 2013-04-17 2023-02-14 Genzyme Corporation Use of an il17 inhibitor for treating and preventing macular degeneration
JP6649250B2 (ja) 2013-05-21 2020-02-19 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 操作されたヘム結合性構成物およびその使用
CA2930693A1 (en) 2013-11-15 2015-05-21 The Board Of Trustees Of The Leland Stanford Junior Unversity Methods of treating heart failure with agonists of hypocretin receptor 2
BR112016017817A2 (pt) 2014-02-06 2017-10-10 Genzyme Corp composições e métodos para o tratamento e a prevenção de degeneração macular
EP3194446B1 (en) 2014-09-18 2022-10-26 Cedars-Sinai Medical Center Compositions and methods for treating fibrosis
WO2016154010A1 (en) 2015-03-20 2016-09-29 Makidon Paul Immunogenic compositions for use in vaccination against bordetella
EP3283529B1 (en) 2015-04-17 2023-06-07 The General Hospital Corporation Agents, systems and methods for treating cancer
US12551526B2 (en) 2015-04-22 2026-02-17 Cedars-Sinai Medical Center Enterically delivered bitter oligopeptides for the treatment for type 2 diabetes
ES2959642T3 (es) 2015-05-13 2024-02-27 The Us Secretary Of The Department Of Health And Human Services Metodos y composiciones para inducir una respuesta inmunitaria mediante construcciones con elementos conservados
WO2016196366A1 (en) 2015-05-29 2016-12-08 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Extension of replicative lifespan in diseases of premature aging using p53 isoforms
US10550379B2 (en) 2015-06-29 2020-02-04 The Board Of Trustees Of The Leland Stanford Junior University Degron fusion constructs and methods for controlling protein production
WO2017096432A1 (en) 2015-12-09 2017-06-15 Admedus Vaccines Pty Ltd Immunomodulating composition for treatment
WO2017222911A1 (en) 2016-06-20 2017-12-28 The Board Of Trustees Of The Leland Stanford Junior University Circular rnas and their use in immunomodulation
WO2018018082A1 (en) 2016-07-26 2018-02-01 The Australian National University Immunostimulatory compositions and uses therefor
CN111344403B (zh) 2017-09-15 2025-05-06 利兰斯坦福初级大学董事会 遗传工程细胞的多元性产生和条形码编制
US10917454B1 (en) 2019-08-01 2021-02-09 Rohde & Schwarz Gmbh & Co. Kg System and method for ATC voice quality assurance
US20250011787A1 (en) 2021-10-21 2025-01-09 The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glads Retroelement-generated transcription factor decoys
WO2023077147A2 (en) 2021-11-01 2023-05-04 Pellis Therapeutics, Inc. T-cell vaccines for patients with reduced humoral immunity
CA3237482A1 (en) 2021-11-03 2023-05-11 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Precise genome editing using retrons
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2023183627A1 (en) 2022-03-25 2023-09-28 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Production of reverse transcribed dna (rt-dna) using a retron reverse transcriptase from exogenous rna
EP4499822A1 (en) 2022-03-25 2025-02-05 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Rt-dna fidelity and retron genome editing
EP4499839A1 (en) 2022-03-25 2025-02-05 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Methods of assessing engineered retron activity, and uses thereof
JP2025525569A (ja) 2022-07-18 2025-08-05 レナゲード セラピューティクス マネージメント インコーポレイテッド 遺伝子編集成分、システム、及び使用方法
US20250243516A1 (en) 2022-08-24 2025-07-31 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Dual Cut Retron Editors for Genomic Insertions and Deletions
WO2024044723A1 (en) 2022-08-25 2024-02-29 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2024233791A1 (en) 2023-05-11 2024-11-14 Seelos Therapeutics, Inc. Methods of treating neurodegenerative disorders
AU2024357861A1 (en) 2023-10-12 2026-04-23 Renagade Therapeutics Management Inc. Nickase-retron template-based precision editing system and methods of use
WO2025155753A2 (en) 2024-01-17 2025-07-24 Renagade Therapeutics Management Inc. Improved gene editing system, guides, and methods

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK489481A (da) * 1980-11-10 1982-05-11 Searle & Co Plasmidvektor og frmgangsmaade til fremstilling deraf
US4603112A (en) * 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
AU570940B2 (en) * 1982-11-30 1988-03-31 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Process for producing poxvirus recombinants for expression offoreign genes
FR2563434B1 (fr) * 1984-04-25 1986-07-25 Transgene Sa Vaccin contre la rage et procede pour sa preparation
EP0190254A4 (en) * 1984-07-05 1987-03-09 Genex Corp GENE CLONE AND PROCESS FOR THE PREPARATION AND USE THEREOF.
DD235669A1 (de) * 1985-03-26 1986-05-14 Akad Wissenschaften Ddr Verfahren zur herstellung eines blv-kodierten huellproteins
WO1986005806A1 (en) * 1985-03-29 1986-10-09 National Research Development Corporation Infectious bronchitis virus spike protein
EP0213894A3 (en) * 1985-08-23 1987-10-21 Advanced Genetics Research Institute Defective viral particle vaccines and methods for their use
AU607399B2 (en) * 1985-09-09 1991-03-07 Cetus Corporation Infectious recombinant virus vaccine for feline leukemia
NZ217645A (en) * 1985-09-25 1991-11-26 Oncogen Recombinant viruses expressing lav/htlv-iii related epitopes and vaccine formulations
AU602875B2 (en) * 1985-12-18 1990-11-01 British Technology Group Limited Newcastle disease virus gene clones
AU8075787A (en) * 1986-09-22 1988-04-07 Australian National University, The Recombinant poxviruses
WO1988002022A1 (en) * 1986-09-22 1988-03-24 Commonwealth Scientific And Industrial Research Or Recombinant poxviruses
EP0261940A3 (en) * 1986-09-23 1989-07-05 Applied Biotechnology, Inc. Pseudorabies vaccines and dna vectors for recombination with pox viruses
AU605567B2 (en) * 1987-03-11 1991-01-17 Nippon Zeon Co., Ltd. Recombinant avipoxvirus
DE10399032I1 (de) * 1987-08-28 2004-01-29 Health Research Inc Rekombinante Viren.
GB8724885D0 (en) * 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
FR2632863B2 (fr) * 1987-10-29 1990-08-31 Transgene Sa Virus du fowlpox recombinant et vaccins derives de ces virus
JP2538367B2 (ja) * 1988-06-24 1996-09-25 ブリティッシュ・テクノロジー・グループ・リミテッド Ｆｏｗｌｐｏｘウィルスの非必須領域
WO1990010693A1 (en) * 1989-03-08 1990-09-20 Health Research, Inc. Recombinant poxvirus host selection system
DE69132311T2 (de) * 1990-09-25 2000-12-14 Cantab Pharmaceuticals Research Ltd., Cambridge Bei einer transkomplementenden zellinie erzeugter defektiver virenimpfstoff

Also Published As

Publication number Publication date
JP3826055B2 (ja) 2006-09-27
IT8821772A0 (it) 1988-08-29
DK175904B1 (da) 2005-06-06
IT1229484B (it) 1991-09-03
KR890701757A (ko) 1989-12-21
CH679934A5 (https=) 1992-05-15
LU91039I2 (fr) 2003-11-05
AR241939A1 (es) 1993-01-29
AU1628895A (en) 1995-08-17
DE10299049I1 (de) 2004-07-01
NL300130I1 (nl) 2003-09-01
CH679933A5 (https=) 1992-05-15
NZ225970A (en) 1991-01-29
DK203689D0 (da) 1989-04-27
NL300130I2 (nl) 2005-11-01
GB2217718A (en) 1989-11-01
GB2217718B (en) 1992-05-20
DE3890874C5 (de) 2005-10-20
IL87581A0 (en) 1989-01-31
JP2002186494A (ja) 2002-07-02
LU90951I2 (fr) 2003-01-15
FR2621487A1 (fr) 1989-04-14
DK203689A (da) 1989-06-27
NL300139I1 (nl) 2004-02-02
NL300138I2 (nl) 2004-03-01
DE10399031I1 (de) 2004-01-29
JPH02500879A (ja) 1990-03-29
GB8908921D0 (en) 1989-08-02
AU690210B2 (en) 1998-04-23
ATA900788A (de) 1995-05-15
NL300138I1 (nl) 2004-02-02
AU2427588A (en) 1989-05-02
WO1989003429A1 (en) 1989-04-20
BE1002134A5 (fr) 1990-07-24
KR970011149B1 (ko) 1997-07-07
JP3348156B2 (ja) 2002-11-20
JP2002348255A (ja) 2002-12-04
NL195051C (nl) 2003-07-01
AT408549B (de) 2001-12-27
NL8820679A (nl) 1989-07-03
DE10399032I1 (de) 2004-01-29
DE3890874C2 (de) 2003-03-13

Similar Documents

Publication Publication Date Title
FR2621487B1 (fr) Virus avipox recombinant
DK603888A (da) Rekombinant virus
ATA902590A (de) Rekombinantes pockenvirus
DE3853088D1 (de) Rekombinantes Avipoxvirus.
ATA257190A (de) Virales polypeptid
FI874819L (fi) Human rekombinant endotelcell vaextfaktor.
DE3850019D1 (de) Rekombinantes Avipoxvirus.
FI892714A0 (fi) Rekombinant-coccidiosisvaccin.
DK97790D0 (da) Renin-inhiberende peptider
FR2620459B1 (fr) Virus recombinant de la vaccine
DK0517292T3 (da) Rekombinant Avipox-virus
DK353788A (da) Polypeptidderivater
DK551287A (da) Polypeptid
DK531986D0 (da) Peptider
DK354487A (da) Oncogen-relaterede peptider
DK377787A (da) Interferonfragmenter
FI864626L (fi) Rekombinantricintoxin.
DK219187A (da) Rekombinant-virus
DE3890874T1 (de) Rekombinante avipoxviren
DK596888D0 (da) Rekombinant lymfotoksin
ZA886415B (en) Recombinant avipox virus
DE3990262T1 (de) Rekombinante retroviren
DK91586D0 (da) Peptider
DK434986D0 (da) Peptider
DK435086D0 (da) Peptider

Legal Events

Date Code Title Description
CP Supplementary protection certificate (spc) filed

Free format text: PRODUCT NAME: VIRUS CANARYPOX RECOMBINANT FELV (VCP97);VIRUS ATTENUE DE LA PANLEUCOPENIE INFECTIEUSE DU CHAT (PLI IV);ANTIGENE DE L HERPESVIRUS FELIN TYPE 1 (C27); ANTIGENE DU CALICIVIRUS FELIN (FCV255); REGISTRATION NO/DATE: EU/2/02/031/001-002 20020308

Spc suppl protection certif: 02C0032

Filing date: 20020904

CR Request for supplementary protection certificate laid open to the public (eec regulation of 18 june 1992)

Free format text: 02C0032, 20020904

CP Supplementary protection certificate (spc) filed
CP Supplementary protection certificate (spc) filed

Free format text: PRODUCT NAME: VIRUS CANARYPOX RECOMBINE GRIPPE A/EQUI-2/KENTUCKY 94; VIRUS CANARYPOX RECOMBINE GRIPPE A/EQUI-2/NEWMARKET/2/93; REGISTRATION NO/DATE: EU/2/03/037/001-004 20030306

Spc suppl protection certif: 03C0032

Filing date: 20030827

Free format text: PRODUCT NAME: VIRUS CANARYPOX RECOMBINE GRIPPE A/EQUI-2/KENTUCKY 94; VIRUS CANARYPOX RECOMBINE GRIPPE A/EQUI-2/NEWMARKET/2/93; ANATOXINE CLOSTRIDIUM TETANI; REGISTRATION NO/DATE: EU/2/03/038/001-004 20030306

Spc suppl protection certif: 03C0031

Filing date: 20030827

CR Request for supplementary protection certificate laid open to the public (eec regulation of 18 june 1992)

Free format text: 03C0032, 20030827

Spc suppl protection certif: 03C0032

Filing date: 20030827

Free format text: 03C0031, 20030827

Spc suppl protection certif: 03C0031

Filing date: 20030827

CP Supplementary protection certificate (spc) filed
CP Supplementary protection certificate (spc) filed

Free format text: PRODUCT NAME: VIRUS RECOMBINANT DE LA GRIPPE AVIAIRE (H5) VECTORISE (VIRUS FOWLPOX); NAT. REGISTRATION NO/DATE: ATVAP 05/017 20060210; FIRST REGISTRATION: FR - ATVAP 05/017 20060210

Spc suppl protection certif: 06C0020

Filing date: 20060626

CR Request for supplementary protection certificate laid open to the public (eec regulation of 18 june 1992)

Free format text: PRODUCT NAME: VIRUS RECOMBINANT DE LA GRIPPE AVIAIRE (H5) VECTORISE (VIRUS FOWLPOX); REGISTRATION NO/DATE IN FRANCE: ATVAP 05/017 DU 20060210; REGISTRATION NO/DATE AT EEC: ATVAP 05/17 DU 20060210

Spc suppl protection certif: 06C0020

Filing date: 20060626

CP Supplementary protection certificate (spc) filed
CY Supplementary certificate of protection granted (eec regulation of 18 june 1992)

Free format text: PRODUCT NAME: VIRUS RECOMBINANT DE LA GRIPPE AVIAIRE (H5) VECTORISE (VIRUS FOWLPOX); REGISTRATION NO/DATE IN FRANCE: ATVAP 05/17 DU 20060210; REGISTRATION NO/DATE AT EEC: ATVAP 05/17 DU 20060210

Spc suppl protection certif: 06C0020

Filing date: 20060626

Extension date: 20130828

CY Supplementary certificate of protection granted (eec regulation of 18 june 1992)

Free format text: PRODUCT NAME: VIRUS CANARYPOX RECOMBINE GRIPPE A/EQUI-/ KENTUCKY/94 + VIRUS CANARYPOX RECOMBINE GRIPPE A/EQUI-2/NEWMARKET2/93; REGISTRATION NO/DATE IN FRANCE: EU/2/03/037/001 DU 20030306; REGISTRATION NO/DATE AT EEC: EU/2/03/307/001-004 DU 20030306

Spc suppl protection certif: 03C0032

Filing date: 20030827

Extension date: 20130828

AV Other action affecting the existence or the validity of an industrial property right

Spc suppl protection certif: 03C0032

CX Request for supplementary protection certificate (spc) rejected

Free format text: PRODUCT NAME: VIRUS CANARYPOX RECOMBINANT FEL V (VCP97); REGISTRATION NO/DATE IN FRANCE: EU/2/02/031/001 DU 20020308; REGISTRATION NO/DATE AT EEC: EU/2/02/031/001-002 DU 20020308

Spc suppl protection certif: 02C0032

Filing date: 20020904

AV Other action affecting the existence or the validity of an industrial property right